The detectability of psilocybin and psilocin, the psychoactive compounds found in certain fungi, in standard drug screenings is generally limited. Common drug tests, such as urine drug screens, are primarily designed to identify substances like opioids, amphetamines, cocaine, and marijuana. Psilocybin and psilocin are metabolized relatively quickly by the body, and tests specifically targeting these compounds are not typically included in routine panels. Therefore, the presence of these substances is unlikely to be revealed during a standard drug screening.
The impermanence of psilocybin and psilocin in the body, combined with the higher cost and complexity of specific detection methods, contributes to their absence from standard drug tests. Historically, concern over psychoactive substance use has focused on substances with higher addiction potential and greater societal impact. Consequently, resources and development have been directed towards detecting those substances more readily, leaving less common hallucinogens like psilocybin outside the scope of most workplace or legal drug screening programs.
